AbbVie’s Skyrizi helps more Crohn’s patients stay off steroids than J&J’s Stelara, PhIII data show

Ab­b­Vie’s Skyrizi has demon­strat­ed sig­nif­i­cant­ly high­er rates of steroid-free clin­i­cal and en­do­scop­ic re­mis­sion ver­sus ri­val John­son & John­son’s Ste­lara in a Phase III tri­al, help­ing set the Crohn’s dis­ease drug apart in an in­creas­ing­ly com­pet­i­tive mar­ket.

Ste­lara won an FDA ap­proval for Crohn’s dis­ease in 2016, while Skyrizi was ap­proved three years lat­er in 2019. But the com­pe­ti­tion is heat­ing up with Ste­lara biosim­i­lars set to en­ter the mar­ket in 2025, gov­ern­ment price ne­go­ti­a­tions in 2026, and a new ri­val emerg­ing in the form of Pfiz­er’s oral S1P in­hibitor Vel­sip­i­ty for ul­cer­a­tive col­i­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.